Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience

Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348(9034):1049–54. Ajani, 2008, Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial, JAMA, 299, 1914, 10.1001/jama.299.16.1914 Bartelink, 1997, J Clin Oncol, 15, 2040, 10.1200/JCO.1997.15.5.2040 Flam, 1996, Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study, J Clin Oncol, 14, 2527, 10.1200/JCO.1996.14.9.2527 Gunderson, 2012, Long-term update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin, J Clin Oncol, 30, 4344, 10.1200/JCO.2012.43.8085 James, 2013, Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial, Lancet Oncol, 14, 516, 10.1016/S1470-2045(13)70086-X Nigro, 1974, Combined therapy for cancer of the anal canal: a preliminary report, Dis Colon Rectum, 17, 354, 10.1007/BF02586980 Kachnic, 2013, RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal, Int J Radiat Oncol Biol Phys, 86, 27, 10.1016/j.ijrobp.2012.09.023 Neibart, 2020, Quality of life after radiotherapy for rectal and anal cancer, Curr Colorectal Cancer Rep, 16, 1, 10.1007/s11888-019-00448-w Shakir, 2020, Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma, Int J Radiat Oncol Biol Phys, 106, 329, 10.1016/j.ijrobp.2019.10.016 Bryant, 2018, Intensity modulated radiation therapy versus conventional radiation for anal cancer in the veterans affairs system, Int J Radiat Oncol Biol Phys, 102, 109, 10.1016/j.ijrobp.2018.05.044 Call, 2016, Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study, Am J Clin Oncol, 39, 8, 10.1097/COC.0000000000000009 Jones, 2018, Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort, Int J Radiat Oncol Biol Phys, 101, 1202, 10.1016/j.ijrobp.2018.04.033 Mitra, 2017, Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529, Adv Radiat Oncol, 2, 110, 10.1016/j.adro.2017.01.009 Franco, 2018, Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study, Radiat Oncol, 13, 172, 10.1186/s13014-018-1124-9 Arcadipane, 2018, Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer, Asia Pac J Clin Oncol, 14, 217, 10.1111/ajco.12768 Mitchell, 2014, Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity, Am J Clin Oncol, 37, 461, 10.1097/COC.0b013e31827e52a3 Vendrely, 2015, French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients, Radiat Oncol, 10, 170, 10.1186/s13014-015-0477-6 Han, 2014, Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer, Int J Radiat Oncol Biol Phys, 90, 587, 10.1016/j.ijrobp.2014.06.061 Joseph, 2015, Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer, Radiother Oncol, 117, 234, 10.1016/j.radonc.2015.08.008 Franco, 2015, Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series, Cancer Invest, 33, 259, 10.3109/07357907.2015.1028586 Salama, 2007, Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience, J Clin Oncol, 25, 4581, 10.1200/JCO.2007.12.0170 Foster, 2018, Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy, PLoS One, 13, e0194234, 10.1371/journal.pone.0194234 Pepek, 2010, Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis, Int J Radiat Oncol Biol Phys, 78, 1413, 10.1016/j.ijrobp.2009.09.046 Kachnic, 2012, Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy, Int J Radiat Oncol Biol Phys, 82, 153, 10.1016/j.ijrobp.2010.09.030 Yates, 2015, Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions, Clin Oncol (R Coll Radiol), 27, 700, 10.1016/j.clon.2015.08.006 Vieillot, 2012, IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center, Radiat Oncol, 7, 45, 10.1186/1748-717X-7-45 Call, 2013, Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: a retrospective review from a large academic center, Pract Radiat Oncol, 3, 26, 10.1016/j.prro.2012.02.005 Janssen, 2014, Clinical experience of SIB-IMRT in anal cancer and selective literature review, Radiat Oncol, 9, 199, 10.1186/1748-717X-9-199 Myerson, 2009, Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas, Int J Radiat Oncol Biol Phys, 74, 824, 10.1016/j.ijrobp.2008.08.070 Ng, 2012, Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer, Int J Radiat Oncol Biol Phys, 83, 1455, 10.1016/j.ijrobp.2011.12.058 ECOG-ACRIN trial 2165: nivolumab after combined modality therapy in treating patients with high risk stage II-IIIB anal cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT03233711. ECOG-ACRIN trial 2182: lower-dose chemoradiation in treating patients with early-stage anal cancer, the DECREASE study. PLATO – personalising anal cancer radiotherapy dose. Available from: http://www.isrctn.com/ISRCTN88455282. Lerman, 2020, Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer, Eur J Cancer, 141, 143, 10.1016/j.ejca.2020.09.039 Alsadius, 2011, Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer, Radiother Oncol, 101, 495, 10.1016/j.radonc.2011.06.010 Eifel, 2002, Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer, J Clin Oncol, 20, 3651, 10.1200/JCO.2002.10.128 Ben-Josef, 2010, Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87–04 and 98–11, J Clin Oncol, 28, 5061, 10.1200/JCO.2010.29.1351 Glynne-Jones, 2020, Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus. Results of a post-hoc analysis from the randomized phase III ACT II trial, Ann Oncol, 10.1016/j.annonc.2020.06.012 Rosenthal, 2017, Final report of a prospective randomized trial to evaluate the dose-response relationship for postoperative radiation therapy and pathologic risk groups in patients with head and neck cancer, Int J Radiat Oncol Biol Phys, 98, 1002, 10.1016/j.ijrobp.2017.02.218 Gunderson, 2013, Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98–11 phase 3 trial, Int J Radiat Oncol Biol Phys, 87, 638, 10.1016/j.ijrobp.2013.07.035 Chakravarthy, 2011, Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292), Int J Radiat Oncol Biol Phys, 81, e607, 10.1016/j.ijrobp.2011.02.042 Konski, 2008, Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92–08, Int J Radiat Oncol Biol Phys, 72, 114, 10.1016/j.ijrobp.2007.12.027 Peiffert, 2012, Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial, J Clin Oncol, 30, 1941, 10.1200/JCO.2011.35.4837 Oehler-Jänne, 2008, HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy, J Clin Oncol, 26, 2550, 10.1200/JCO.2007.15.2348 Gilbert, 2013, p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy, Radiother Oncol, 109, 146, 10.1016/j.radonc.2013.08.002